Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.

about

Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.

Item

http://www.wikidata.org/entity/Q38925652

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Six-year multi-centre, observa ...... men aged 10-25 years in Korea.

@en

type

Item

label

Six-year multi-centre, observa ...... men aged 10-25 years in Korea.

@en

prefLabel

Six-year multi-centre, observa ...... men aged 10-25 years in Korea.

@en

P1476

Six-year multi-centre, observa ...... men aged 10-25 years in Korea.

@en

P2093

Chul-Jung Kim

http://www.w3.org/2001/XMLSchema#string

Dan Bi

http://www.w3.org/2001/XMLSchema#string

Fernanda Tavares Da Silva

http://www.w3.org/2001/XMLSchema#string

Jing Chen

http://www.w3.org/2001/XMLSchema#string

Joon Hyung Kim

http://www.w3.org/2001/XMLSchema#string

Kusuma B Gopala

http://www.w3.org/2001/XMLSchema#string

Rok Song

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

HPV vaccination crisis in Japan

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Safety of human papillomavirus vaccines: a review.

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.

Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study

Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

P304

837-842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.4175

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jong Sup Park

P577

2017-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28266092

http://www.w3.org/2001/XMLSchema#string

P932

5516175

http://www.w3.org/2001/XMLSchema#string